
HCW Biologics Inc. (NASDAQ:HCWB) shares were up Monday after the company announced a breakthrough in developing second-generation pembrolizumab-based immunotherapies for solid tumors.
What to Know: The company said its proprietary TRBC product discovery platform produced fusion molecules that enhance immune activation and tumor infiltration, showing strong preclinical results particularly against pancreatic and ovarian cancers.